AGÕæÈ˹ٷ½

STOCK TITAN

[Form 3] Shattuck Labs, Inc. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3
Rhea-AI Filing Summary

OrbiMed entities and OrbiMed Advisors LLC reported their relationship to Shattuck Labs (STTK) as directors but stated they do not beneficially own any securities of the issuer. The Form 3 lists three reporting entities at the same New York address and indicates the filing covers more than one reporting person. No non‑derivative or derivative holdings are reported.

Le entità di OrbiMed e OrbiMed Advisors LLC hanno dichiarato la loro posizione in Shattuck Labs (STTK) come amministratori, precisando però di non detenere utilmente alcun titolo dell'emittente. Il modulo Form 3 riporta tre soggetti segnalanti con lo stesso indirizzo a New York e indica che la comunicazione riguarda più persone segnalanti. Non sono riportate partecipazioni né non‑derivate né derivate.

Las entidades de OrbiMed y OrbiMed Advisors LLC informaron su relación con Shattuck Labs (STTK) como directores, pero señalaron que no poseen de forma beneficiaria valores del emisor. El Formulario 3 lista tres entidades informantes en la misma dirección de Nueva York e indica que la presentación abarca a más de una persona informante. No se registran participaciones no derivadas ni derivadas.

OrbiMed ì†Œì† ë²•ì¸ë“¤ê³¼ OrbiMed Advisors LLCëŠ� Shattuck Labs(STTK)와ì� 관계를 ì´ì‚¬ë¡� 보고하면서ë„, ë°œí–‰ì‚¬ì˜ ì¦ê¶Œì� 실질ì ìœ¼ë¡� 보유하고 있지 않다ê³� ë°í˜”습니ë‹�. Form 3ì—는 ë™ì¼í•� 뉴욕 주소ì—� 등ë¡ë� ì„� ê°œì˜ ì‹ ê³  주체가 기재ë˜ì–´ 있으ë©� 제출 서류가 여러 ì‹ ê³ ì¸ì„ í¬í•¨í•¨ì„ 나타냅니ë‹�. 비파ìƒ�(순수 ì§€ë¶�)ì´ë‚˜ 파ìƒìƒí’ˆ 보유ëŠ� ë³´ê³ ë˜ì§€ 않았습니ë‹�.

Les entités d'OrbiMed et OrbiMed Advisors LLC ont indiqué leur lien avec Shattuck Labs (STTK) en tant qu'administrateurs, tout en précisant qu'elles ne détiennent aucun titre à leur avantage de l'émetteur. Le formulaire 3 mentionne trois entités déclarantes à la même adresse new-yorkaise et précise que le dépôt concerne plusieurs personnes déclarante. Aucune détention non dérivée ni dérivée n'est déclarée.

OrbiMed-Einheiten und OrbiMed Advisors LLC meldeten ihre Beziehung zu Shattuck Labs (STTK) als Direktoren, gaben jedoch an, keine wirtschaftlich begünstigten Wertpapiere des Emittenten zu besitzen. Das Formular 3 führt drei meldende Stellen unter derselben New Yorker Adresse auf und weist darauf hin, dass die Einreichung mehrere meldepflichtige Personen umfasst. Es sind weder nicht‑derivative noch derivative Bestände gemeldet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Reporting parties are directors of STTK and report zero beneficial ownership, a routine initial Form 3 disclosure.

This initial Form 3 notifies the market that OrbiMed Advisors LLC, OrbiMed Capital GP IX LLC and OrbiMed Genesis GP LLC are related to Shattuck Labs as directors but currently hold no reported non‑derivative or derivative securities. The disclosure is administrative and does not reflect transactions, ownership stakes, or material changes to capital structure. Investor impact is minimal absent subsequent purchases or grants.

TL;DR: Governance disclosure confirms director relationships without revealing ownership; no material governance or control concerns shown.

The filing documents director status for multiple affiliated reporting entities sharing the same address and signatory, and explicitly states "No securities are beneficially owned." From a governance perspective, this is a standard declaration. It raises no immediate governance flags such as undisclosed related‑party holdings or conflicting ownership claims. Materiality remains low until holdings or transactions are reported.

Le entità di OrbiMed e OrbiMed Advisors LLC hanno dichiarato la loro posizione in Shattuck Labs (STTK) come amministratori, precisando però di non detenere utilmente alcun titolo dell'emittente. Il modulo Form 3 riporta tre soggetti segnalanti con lo stesso indirizzo a New York e indica che la comunicazione riguarda più persone segnalanti. Non sono riportate partecipazioni né non‑derivate né derivate.

Las entidades de OrbiMed y OrbiMed Advisors LLC informaron su relación con Shattuck Labs (STTK) como directores, pero señalaron que no poseen de forma beneficiaria valores del emisor. El Formulario 3 lista tres entidades informantes en la misma dirección de Nueva York e indica que la presentación abarca a más de una persona informante. No se registran participaciones no derivadas ni derivadas.

OrbiMed ì†Œì† ë²•ì¸ë“¤ê³¼ OrbiMed Advisors LLCëŠ� Shattuck Labs(STTK)와ì� 관계를 ì´ì‚¬ë¡� 보고하면서ë„, ë°œí–‰ì‚¬ì˜ ì¦ê¶Œì� 실질ì ìœ¼ë¡� 보유하고 있지 않다ê³� ë°í˜”습니ë‹�. Form 3ì—는 ë™ì¼í•� 뉴욕 주소ì—� 등ë¡ë� ì„� ê°œì˜ ì‹ ê³  주체가 기재ë˜ì–´ 있으ë©� 제출 서류가 여러 ì‹ ê³ ì¸ì„ í¬í•¨í•¨ì„ 나타냅니ë‹�. 비파ìƒ�(순수 ì§€ë¶�)ì´ë‚˜ 파ìƒìƒí’ˆ 보유ëŠ� ë³´ê³ ë˜ì§€ 않았습니ë‹�.

Les entités d'OrbiMed et OrbiMed Advisors LLC ont indiqué leur lien avec Shattuck Labs (STTK) en tant qu'administrateurs, tout en précisant qu'elles ne détiennent aucun titre à leur avantage de l'émetteur. Le formulaire 3 mentionne trois entités déclarantes à la même adresse new-yorkaise et précise que le dépôt concerne plusieurs personnes déclarante. Aucune détention non dérivée ni dérivée n'est déclarée.

OrbiMed-Einheiten und OrbiMed Advisors LLC meldeten ihre Beziehung zu Shattuck Labs (STTK) als Direktoren, gaben jedoch an, keine wirtschaftlich begünstigten Wertpapiere des Emittenten zu besitzen. Das Formular 3 führt drei meldende Stellen unter derselben New Yorker Adresse auf und weist darauf hin, dass die Einreichung mehrere meldepflichtige Personen umfasst. Es sind weder nicht‑derivative noch derivative Bestände gemeldet.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
ORBIMED ADVISORS LLC

(Last) (First) (Middle)
601 LEXINGTON AVENUE
54TH FLOOR

(Street)
NEW YORK NY 10022

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
08/25/2025
3. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
ORBIMED ADVISORS LLC

(Last) (First) (Middle)
601 LEXINGTON AVENUE
54TH FLOOR

(Street)
NEW YORK NY 10022

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
X Director 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
OrbiMed Capital GP IX LLC

(Last) (First) (Middle)
601 LEXINGTON AVENUE
54TH FLOOR

(Street)
NEW YORK NY 10022

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
X Director 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
OrbiMed Genesis GP LLC

(Last) (First) (Middle)
601 LEXINGTON AVENUE, 54TH FLOOR

(Street)
NEW YORK NY 10022

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
X Director 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
No securities are beneficially owned.
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC 09/02/2025
/s/ Carl L. Gordon, Member of OrbiMed Capital GP IX LLC 09/02/2025
/s/ Carl L. Gordon, Member of OrbiMed Genesis GP LLC 09/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 filed for Shattuck Labs (STTK) disclose?

The Form 3 discloses that OrbiMed Advisors LLC, OrbiMed Capital GP IX LLC, and OrbiMed Genesis GP LLC are related to the issuer as directors and that no securities are beneficially owned by these reporting persons.

Which entities filed the initial statement for STTK?

The filing names OrbiMed Advisors LLC, OrbiMed Capital GP IX LLC, and OrbiMed Genesis GP LLC at the same New York address as the reporting parties.

Does the Form 3 report any stock options or derivative holdings for STTK?

No. The Form 3 shows no non‑derivative or derivative securities beneficially owned by the reporting persons.

Is this Form 3 reporting a change in ownership or a transaction for STTK?

No. The Form 3 is an initial statement indicating director relationships and explicitly states that there are no securities owned; it does not report purchases, sales, or ownership changes.
Shattuck Labs, Inc.

NASDAQ:STTK

STTK Rankings

STTK Latest News

STTK Latest SEC Filings

STTK Stock Data

46.98M
40.71M
14.36%
59.03%
0.9%
Biotechnology
Pharmaceutical Preparations
United States
AUSTIN